Research graph
References from Evidence for DNA Damage Checkpoint Activation in Barrett Esophagus. Local targets link to admitted publications; unresolved targets remain external evidence.
Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
10.1016/0016-5085(87)90847-x · 1987 · External reference
The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years
1997 · External reference
Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort
10.1111/j.1572-0241.2005.41300.x · 2005 · External reference
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
10.1056/nejm199903183401101 · 1999 · External reference
Dysplasia in Barrett's esophagus: limitations of current management strategies
10.1111/j.1572-0241.2005.41201.x · 2005 · External reference
Radiofrequency ablation in Barrett's esophagus with dysplasia
10.1056/nejmoa0808145 · 2009 · External reference
Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists
10.1111/j.1365-2559.2007.02706.x · 2007 · External reference
Observer variation in the diagnosis of dysplasia in Barrett's esophagus
10.1016/s0046-8177(88)80344-7 · 1988 · External reference
Chromosomal instability in Barrett's esophagus is related to telomere shortening
10.1158/1055-9965.epi-05-0837 · 2006 · External reference
GERD is associated with shortened telomeres in the squamous epithelium of the distal esophagus
10.1152/ajpgi.00055.2007 · 2007 · External reference
Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinomasequence of Barrett's esophagus
2000 · External reference
Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance
10.1158/1078-0432.ccr-06-1385 · 2007 · External reference
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue
10.1093/jnci/91.24.2087 · 1999 · External reference
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma
10.1371/journal.pmed.0040067 · 2007 · External reference
Biomarkers in Barrett's esophagus
10.1016/s1052-5157(03)00006-0 · 2003 · External reference
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study
10.1016/s1470-2045(05)70431-9 · 2005 · External reference
Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH
10.1002/gcc.20435 · 2007 · External reference
DNA damage checkpoints: from initiation to recovery or adaptation
10.1016/j.ceb.2007.02.009 · 2007 · External reference
Transgenic expression of VEGF in intestinal epithelium drives mesenchymal cell interactions and epithelial neoplasia
10.1053/j.gastro.2008.10.028 · 2009 · External reference
p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation
10.1053/gast.2000.17952 · 2000 · External reference
Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a)
10.1128/mcb.19.5.3916 · 1999 · External reference
The DNA damage response: putting checkpoints in perspective
10.1038/35044005 · 2000 · External reference
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control
10.1038/nature02820 · 2004 · External reference
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice
10.1016/j.ccr.2006.10.019 · 2007 · External reference
Aurora-B phosphorylates histone H3 at serine28 with regard to the mitotic chromosome condensation
10.1046/j.1356-9597.2001.00498.x · 2002 · External reference
A DNA damage checkpoint response in telomere-initiated senescence
10.1038/nature02118 · 2003 · External reference
Substrate specificities and identification of putative substrates of ATM kinase family members
10.1074/jbc.274.53.37538 · 1999 · External reference
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
10.1126/science.1140321 · 2007 · External reference
p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
10.1038/sj.onc.1203013 · 1999 · External reference
Induction of the tumor-suppressor p16(INK4a) within regenerative epithelial crypts in ulcerative colitis
10.1593/neo.06169 · 2006 · External reference
Requirement for p53 and p21 to sustain G2 arrest after DNA damage
10.1126/science.282.5393.1497 · 1998 · External reference
A role for ATR in the DNA damage- induced phosphorylation of p53
10.1101/gad.13.2.152 · 1999 · External reference
Surfing the p53 network
10.1038/35042675 · 2000 · External reference
Clinical use of p53 in Barrett's esophagus
10.1158/1055-9965.epi-06-0010 · 2006 · External reference
Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus
10.1111/j.1365-2559.2005.02139.x · 2005 · External reference
p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus
10.1016/j.canlet.2004.01.020 · 2004 · External reference
P53 protein and malignant progression in Barrett's metaplasia (Barrett's esophagus)
10.1111/j.1572-0241.2003.07447.x · 2003 · External reference
p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia
10.1023/a:1018828207371 · 1997 · External reference
Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation
10.1111/j.1572-0241.2002.05770.x · 2002 · External reference
p16INK4A participates in a G1 arrest checkpoint in response to DNA damage
10.1128/mcb.18.1.378 · 1998 · External reference
Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus
1996 · External reference
Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma
10.1136/jcp.50.3.212 · 1997 · External reference
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk
10.1038/sj.onc.1208598 · 2005 · External reference
Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
10.1016/s0016-5085(98)70016-2 · 1998 · External reference
Barrett's esophagus and its progression to adenocarcinoma
10.6004/jnccn.2006.0031 · 2006 · External reference
Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus
10.1002/jcp.20590 · 2006 · External reference
Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus
10.1038/sj.onc.1204947 · 2001 · External reference
Cdk inhibition in human cells compromises Chk1 function and activates a DNA damage response
10.1158/0008-5472.780.65.3 · 2005 · External reference
Does acid suppression alter progression in Barrett's esophagus?
10.1111/j.1572-0241.2003.07207.x · 2003 · External reference
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
10.1038/nature05327 · 2006 · External reference
K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction
10.1046/j.1440-1746.2000.02163.x · 2000 · External reference
Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus
10.1136/gut.37.2.168 · 1995 · External reference
